| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 95 | 2025 | 3157 | 15.960 |
Why?
|
| Mastectomy | 51 | 2025 | 270 | 14.320 |
Why?
|
| Carcinoma, Ductal, Breast | 22 | 2022 | 166 | 6.800 |
Why?
|
| Carcinoma, Lobular | 18 | 2019 | 85 | 5.550 |
Why?
|
| Time-to-Treatment | 8 | 2025 | 140 | 4.820 |
Why?
|
| Surgeons | 12 | 2025 | 298 | 4.080 |
Why?
|
| Mastectomy, Segmental | 18 | 2023 | 108 | 3.750 |
Why?
|
| Cancer Care Facilities | 6 | 2025 | 36 | 3.690 |
Why?
|
| Quality Indicators, Health Care | 7 | 2025 | 155 | 3.500 |
Why?
|
| Neoadjuvant Therapy | 11 | 2025 | 449 | 2.910 |
Why?
|
| Mammaplasty | 10 | 2023 | 124 | 2.820 |
Why?
|
| Accreditation | 5 | 2025 | 74 | 2.740 |
Why?
|
| Prophylactic Mastectomy | 8 | 2020 | 13 | 2.650 |
Why?
|
| Neoplasm Staging | 26 | 2025 | 2086 | 2.480 |
Why?
|
| Guideline Adherence | 5 | 2025 | 245 | 2.250 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 7 | 2022 | 126 | 2.160 |
Why?
|
| Prognosis | 28 | 2025 | 4029 | 2.030 |
Why?
|
| Female | 98 | 2025 | 50045 | 2.020 |
Why?
|
| Middle Aged | 70 | 2025 | 28371 | 1.940 |
Why?
|
| Lymph Node Excision | 10 | 2021 | 235 | 1.840 |
Why?
|
| Receptors, Estrogen | 10 | 2022 | 417 | 1.800 |
Why?
|
| Surgical Oncology | 4 | 2020 | 29 | 1.780 |
Why?
|
| Databases, Factual | 19 | 2025 | 1010 | 1.770 |
Why?
|
| Radiation Oncology | 3 | 2021 | 125 | 1.760 |
Why?
|
| Sentinel Lymph Node Biopsy | 12 | 2021 | 86 | 1.750 |
Why?
|
| Follow-Up Studies | 23 | 2025 | 3927 | 1.700 |
Why?
|
| Aged | 56 | 2025 | 20972 | 1.690 |
Why?
|
| Practice Guidelines as Topic | 8 | 2025 | 1096 | 1.690 |
Why?
|
| Humans | 108 | 2025 | 96112 | 1.550 |
Why?
|
| Hospitals, Low-Volume | 2 | 2025 | 22 | 1.450 |
Why?
|
| Aged, 80 and over | 34 | 2023 | 7230 | 1.440 |
Why?
|
| Hospitals, High-Volume | 2 | 2025 | 42 | 1.410 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2020 | 1471 | 1.390 |
Why?
|
| United States | 32 | 2025 | 7768 | 1.390 |
Why?
|
| Adult | 50 | 2025 | 28725 | 1.350 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2019 | 518 | 1.340 |
Why?
|
| Radiotherapy, Adjuvant | 9 | 2021 | 315 | 1.330 |
Why?
|
| Unilateral Breast Neoplasms | 4 | 2020 | 5 | 1.290 |
Why?
|
| Mastectomy, Subcutaneous | 2 | 2022 | 8 | 1.250 |
Why?
|
| Nipples | 6 | 2022 | 38 | 1.220 |
Why?
|
| Patient Reported Outcome Measures | 5 | 2024 | 286 | 1.220 |
Why?
|
| Thoracic Wall | 2 | 2018 | 27 | 1.120 |
Why?
|
| Receptor, ErbB-2 | 5 | 2019 | 280 | 1.100 |
Why?
|
| Lymph Nodes | 4 | 2018 | 565 | 1.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 2642 | 1.060 |
Why?
|
| Breast Diseases | 2 | 2022 | 101 | 1.020 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2020 | 647 | 1.020 |
Why?
|
| Neoplasm Invasiveness | 9 | 2020 | 580 | 0.990 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 186 | 0.980 |
Why?
|
| Ergonomics | 3 | 2022 | 25 | 0.970 |
Why?
|
| Breast Neoplasms, Male | 2 | 2023 | 31 | 0.960 |
Why?
|
| Combined Modality Therapy | 8 | 2021 | 1773 | 0.950 |
Why?
|
| Decision Making | 4 | 2019 | 694 | 0.940 |
Why?
|
| Breast | 6 | 2021 | 297 | 0.920 |
Why?
|
| Neoplasms, Second Primary | 3 | 2017 | 247 | 0.900 |
Why?
|
| Axilla | 11 | 2021 | 110 | 0.890 |
Why?
|
| Receptors, Progesterone | 6 | 2019 | 196 | 0.880 |
Why?
|
| Young Adult | 16 | 2025 | 7025 | 0.870 |
Why?
|
| Biomarkers, Tumor | 5 | 2019 | 1670 | 0.870 |
Why?
|
| Survival Rate | 12 | 2018 | 1985 | 0.860 |
Why?
|
| Retrospective Studies | 25 | 2024 | 10287 | 0.850 |
Why?
|
| Surveys and Questionnaires | 8 | 2023 | 2860 | 0.830 |
Why?
|
| Attitude of Health Personnel | 4 | 2023 | 682 | 0.810 |
Why?
|
| Qualitative Research | 2 | 2024 | 361 | 0.790 |
Why?
|
| Carcinoma | 2 | 2017 | 448 | 0.780 |
Why?
|
| Brachytherapy | 2 | 2014 | 127 | 0.770 |
Why?
|
| Quality Improvement | 3 | 2025 | 502 | 0.750 |
Why?
|
| Early Detection of Cancer | 4 | 2024 | 484 | 0.740 |
Why?
|
| Patient Satisfaction | 5 | 2024 | 514 | 0.730 |
Why?
|
| Organ Sparing Treatments | 2 | 2019 | 47 | 0.720 |
Why?
|
| Medical Overuse | 2 | 2019 | 40 | 0.720 |
Why?
|
| Healthcare Disparities | 3 | 2024 | 491 | 0.700 |
Why?
|
| Neoplasm Grading | 10 | 2018 | 404 | 0.690 |
Why?
|
| Quality of Health Care | 3 | 2018 | 404 | 0.660 |
Why?
|
| Oncologists | 1 | 2021 | 38 | 0.660 |
Why?
|
| Societies, Medical | 3 | 2025 | 644 | 0.640 |
Why?
|
| Lymphatic Metastasis | 7 | 2018 | 514 | 0.600 |
Why?
|
| Age Factors | 9 | 2018 | 1963 | 0.600 |
Why?
|
| Burnout, Professional | 1 | 2021 | 113 | 0.600 |
Why?
|
| Pandemics | 7 | 2025 | 880 | 0.590 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2017 | 154 | 0.590 |
Why?
|
| Stereotaxic Techniques | 1 | 2019 | 85 | 0.580 |
Why?
|
| Prophylactic Surgical Procedures | 2 | 2015 | 7 | 0.570 |
Why?
|
| Patient Selection | 6 | 2019 | 709 | 0.570 |
Why?
|
| Image-Guided Biopsy | 1 | 2019 | 81 | 0.560 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 346 | 0.560 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 334 | 0.560 |
Why?
|
| Radiography, Interventional | 1 | 2019 | 154 | 0.550 |
Why?
|
| Patient Care | 1 | 2019 | 101 | 0.550 |
Why?
|
| Genes, BRCA2 | 3 | 2016 | 162 | 0.540 |
Why?
|
| Genes, BRCA1 | 3 | 2016 | 192 | 0.540 |
Why?
|
| Patient Transfer | 1 | 2018 | 108 | 0.540 |
Why?
|
| Consensus | 2 | 2016 | 370 | 0.530 |
Why?
|
| Reoperation | 5 | 2015 | 707 | 0.530 |
Why?
|
| Radiotherapy, Conformal | 1 | 2017 | 89 | 0.510 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2017 | 296 | 0.510 |
Why?
|
| Logistic Models | 7 | 2017 | 1268 | 0.500 |
Why?
|
| Patient Preference | 4 | 2019 | 126 | 0.490 |
Why?
|
| Adolescent | 9 | 2024 | 9895 | 0.480 |
Why?
|
| Postoperative Complications | 7 | 2016 | 2591 | 0.450 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 569 | 0.450 |
Why?
|
| Prospective Studies | 8 | 2022 | 4672 | 0.440 |
Why?
|
| Estrogen Receptor alpha | 2 | 2013 | 155 | 0.430 |
Why?
|
| Quality of Life | 4 | 2019 | 1816 | 0.420 |
Why?
|
| Incidence | 4 | 2025 | 1715 | 0.420 |
Why?
|
| Biopsy | 5 | 2025 | 1220 | 0.420 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 1876 | 0.400 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 378 | 0.400 |
Why?
|
| Elective Surgical Procedures | 1 | 2014 | 162 | 0.380 |
Why?
|
| Receptors, Notch | 2 | 2010 | 136 | 0.370 |
Why?
|
| Length of Stay | 3 | 2015 | 833 | 0.370 |
Why?
|
| Melanoma | 2 | 2009 | 497 | 0.370 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 188 | 0.360 |
Why?
|
| Skin Neoplasms | 2 | 2009 | 625 | 0.340 |
Why?
|
| Workload | 2 | 2022 | 133 | 0.340 |
Why?
|
| Operating Rooms | 2 | 2022 | 138 | 0.330 |
Why?
|
| Receptor, Notch1 | 2 | 2010 | 101 | 0.320 |
Why?
|
| Mammography | 3 | 2023 | 475 | 0.320 |
Why?
|
| Patient Readmission | 1 | 2014 | 413 | 0.320 |
Why?
|
| Registries | 1 | 2014 | 986 | 0.300 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 2008 | 4 | 0.300 |
Why?
|
| Patients | 2 | 2023 | 108 | 0.290 |
Why?
|
| Socioeconomic Factors | 3 | 2016 | 640 | 0.280 |
Why?
|
| Quality Control | 2 | 2019 | 125 | 0.270 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2010 | 684 | 0.260 |
Why?
|
| Calcinosis | 1 | 2008 | 232 | 0.260 |
Why?
|
| Breast Implantation | 3 | 2016 | 15 | 0.260 |
Why?
|
| Pilot Projects | 3 | 2019 | 938 | 0.250 |
Why?
|
| Risk Factors | 6 | 2019 | 5961 | 0.240 |
Why?
|
| SEER Program | 3 | 2017 | 235 | 0.240 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 1010 | 0.240 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2017 | 935 | 0.240 |
Why?
|
| Health Care Surveys | 2 | 2018 | 295 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3652 | 0.220 |
Why?
|
| Risk Assessment | 4 | 2020 | 2480 | 0.220 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 901 | 0.220 |
Why?
|
| Male | 10 | 2024 | 45871 | 0.210 |
Why?
|
| Referral and Consultation | 2 | 2019 | 386 | 0.210 |
Why?
|
| Appointments and Schedules | 1 | 2024 | 59 | 0.210 |
Why?
|
| Self Concept | 1 | 2023 | 137 | 0.200 |
Why?
|
| Time Factors | 5 | 2016 | 5585 | 0.190 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 482 | 0.190 |
Why?
|
| Cohort Studies | 4 | 2018 | 3110 | 0.160 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 1535 | 0.160 |
Why?
|
| Betacoronavirus | 2 | 2020 | 284 | 0.160 |
Why?
|
| Personnel Selection | 1 | 2020 | 64 | 0.150 |
Why?
|
| Health Resources | 1 | 2020 | 82 | 0.150 |
Why?
|
| Body Image | 1 | 2019 | 84 | 0.150 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 1176 | 0.150 |
Why?
|
| Specialties, Surgical | 1 | 2020 | 77 | 0.150 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2018 | 287 | 0.150 |
Why?
|
| Fear | 1 | 2019 | 88 | 0.150 |
Why?
|
| User-Computer Interface | 1 | 2020 | 196 | 0.150 |
Why?
|
| Triage | 1 | 2020 | 132 | 0.150 |
Why?
|
| Interviews as Topic | 1 | 2020 | 376 | 0.150 |
Why?
|
| Breast Implants | 2 | 2016 | 28 | 0.150 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 319 | 0.140 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 145 | 0.140 |
Why?
|
| Treatment Outcome | 5 | 2018 | 9176 | 0.140 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2018 | 7 | 0.140 |
Why?
|
| Anxiety | 1 | 2021 | 339 | 0.140 |
Why?
|
| Databases as Topic | 1 | 2018 | 96 | 0.140 |
Why?
|
| Video Recording | 1 | 2019 | 214 | 0.140 |
Why?
|
| Emotions | 1 | 2021 | 377 | 0.140 |
Why?
|
| Patient Participation | 1 | 2019 | 242 | 0.130 |
Why?
|
| Patient Compliance | 1 | 2018 | 239 | 0.130 |
Why?
|
| Choice Behavior | 1 | 2018 | 165 | 0.130 |
Why?
|
| Heterozygote | 2 | 2016 | 382 | 0.130 |
Why?
|
| Sleep | 1 | 2021 | 458 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2018 | 713 | 0.130 |
Why?
|
| Telemedicine | 1 | 2020 | 229 | 0.130 |
Why?
|
| Ultrasonography, Mammary | 1 | 2017 | 84 | 0.120 |
Why?
|
| Disease Management | 1 | 2018 | 360 | 0.120 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2017 | 204 | 0.120 |
Why?
|
| Esthetics | 1 | 2016 | 50 | 0.120 |
Why?
|
| Surgical Wound Infection | 2 | 2015 | 237 | 0.120 |
Why?
|
| Watchful Waiting | 1 | 2016 | 71 | 0.120 |
Why?
|
| Molecular Typing | 1 | 2015 | 19 | 0.120 |
Why?
|
| Illinois | 1 | 2017 | 531 | 0.120 |
Why?
|
| Comprehension | 1 | 2016 | 84 | 0.120 |
Why?
|
| Europe | 1 | 2016 | 349 | 0.120 |
Why?
|
| Pharyngectomy | 1 | 2015 | 8 | 0.120 |
Why?
|
| Remission Induction | 1 | 2017 | 769 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2016 | 218 | 0.110 |
Why?
|
| Neoplasms | 2 | 2022 | 3248 | 0.110 |
Why?
|
| Immunohistochemistry | 2 | 2010 | 1829 | 0.110 |
Why?
|
| Physicians | 2 | 2019 | 707 | 0.110 |
Why?
|
| Counseling | 1 | 2016 | 174 | 0.110 |
Why?
|
| Carcinoma in Situ | 1 | 2015 | 53 | 0.110 |
Why?
|
| Selection Bias | 1 | 2014 | 38 | 0.110 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 1094 | 0.110 |
Why?
|
| Linear Models | 1 | 2015 | 438 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1958 | 0.110 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 328 | 0.110 |
Why?
|
| Adipokines | 1 | 2013 | 18 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 501 | 0.100 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 1069 | 0.100 |
Why?
|
| Receptor, Notch4 | 2 | 2010 | 5 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 884 | 0.100 |
Why?
|
| Insurance, Health | 1 | 2014 | 182 | 0.100 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2015 | 149 | 0.100 |
Why?
|
| Fatty Acids | 1 | 2013 | 153 | 0.100 |
Why?
|
| Surgical Flaps | 1 | 2015 | 259 | 0.090 |
Why?
|
| Venous Thromboembolism | 1 | 2015 | 171 | 0.090 |
Why?
|
| Robotic Surgical Procedures | 1 | 2018 | 367 | 0.090 |
Why?
|
| Adipose Tissue | 1 | 2013 | 270 | 0.090 |
Why?
|
| Models, Biological | 1 | 2018 | 1810 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2883 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 1089 | 0.080 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2010 | 13 | 0.080 |
Why?
|
| Jagged-1 Protein | 1 | 2010 | 13 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 491 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 1346 | 0.080 |
Why?
|
| Calcium-Binding Proteins | 1 | 2010 | 120 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 2463 | 0.080 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 190 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2008 | 222 | 0.070 |
Why?
|
| Receptor Cross-Talk | 1 | 2008 | 33 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2009 | 215 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 1105 | 0.070 |
Why?
|
| Hemostatics | 1 | 2008 | 61 | 0.070 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2008 | 74 | 0.070 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 232 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 363 | 0.070 |
Why?
|
| Hyperplasia | 1 | 2008 | 149 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2009 | 179 | 0.070 |
Why?
|
| Cancer Vaccines | 1 | 2009 | 170 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 198 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2008 | 909 | 0.060 |
Why?
|
| Obesity | 1 | 2013 | 1034 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2012 | 2090 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 1196 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2040 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2010 | 1276 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 1807 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 2 | 2013 | 298 | 0.050 |
Why?
|
| Mutation | 1 | 2014 | 4374 | 0.050 |
Why?
|
| Organizational Innovation | 1 | 2020 | 47 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2013 | 1049 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2023 | 565 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 323 | 0.040 |
Why?
|
| Fees and Charges | 1 | 2018 | 14 | 0.040 |
Why?
|
| Hospital Charges | 1 | 2018 | 32 | 0.040 |
Why?
|
| Sentinel Lymph Node | 1 | 2018 | 22 | 0.030 |
Why?
|
| Propensity Score | 1 | 2018 | 180 | 0.030 |
Why?
|
| Mass Screening | 1 | 2022 | 710 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2018 | 340 | 0.030 |
Why?
|
| Urologic Surgical Procedures | 1 | 2018 | 152 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 239 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2017 | 322 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1506 | 0.030 |
Why?
|
| ROC Curve | 1 | 2018 | 797 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1755 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2018 | 480 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 328 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2015 | 125 | 0.030 |
Why?
|
| Communication | 1 | 2018 | 477 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2015 | 182 | 0.030 |
Why?
|
| Lipase | 1 | 2013 | 21 | 0.030 |
Why?
|
| Serpins | 1 | 2013 | 31 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 362 | 0.030 |
Why?
|
| Nerve Growth Factors | 1 | 2013 | 61 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 668 | 0.020 |
Why?
|
| Leptin | 1 | 2013 | 102 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 635 | 0.020 |
Why?
|
| Eye Proteins | 1 | 2013 | 130 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 67 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2012 | 98 | 0.020 |
Why?
|
| Contraindications | 1 | 2012 | 70 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2012 | 366 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 1011 | 0.020 |
Why?
|
| Sepsis | 1 | 2015 | 391 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 815 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2008 | 37 | 0.020 |
Why?
|
| Estradiol | 1 | 2008 | 255 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 528 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 563 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2008 | 830 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 1124 | 0.010 |
Why?
|
| Mice | 1 | 2008 | 12541 | 0.010 |
Why?
|
| Animals | 1 | 2008 | 28919 | 0.000 |
Why?
|